Last updated: February 20, 2026
Bromocriptine mesylate is a dopamine receptor agonist used for Parkinson's disease, hyperprolactinemia, and other endocrine disorders. The drug's supply chain is concentrated among a few key pharmaceutical manufacturers, with various generic producers.
Major Suppliers and Manufacturers
| Company Name |
Location |
Production Highlights |
Market Focus |
Notable Notes |
| GlaxoSmithKline (GSK) |
United Kingdom |
Original patent holder; generic manufacturing |
Global |
Commercial production shifted after patent expiry; now primarily generic supplier |
| Teva Pharmaceutical Industries |
Israel |
Large-scale generic drug producer |
Global |
Maintains significant portfolio of dopamine agonists |
| Apotex |
Canada |
Generic pharmaceuticals |
North America, others |
Produces bromocriptine mesylate as part of broader dopamine agonists portfolio |
| Sun Pharmaceutical Industries |
India |
Leading Indian generic producer |
India, emerging markets |
Manufactures bromocriptine mesylate with global distribution |
| Cipla |
India |
Known for affordable generics |
India, Africa, parts of Asia |
Produces bromocriptine formulations |
| Mylan (Now part of Viatris) |
United States / Europe |
Major generic producer |
North America, Europe |
Develops multiple dosage forms, including tablets |
Regional Suppliers and Market Distribution
-
India: Dominates production with companies like Sun Pharma, Cipla, and Dr. Reddy's. Supplies cover domestic needs and exports to emerging markets.
-
Europe & North America: GSK holds the original patent; after patent expiration, Pfizer, Teva, and Mylan increased generic manufacturing.
-
Asia: India and China have major manufacturing capacities, providing low-cost options worldwide.
Supply Chain Considerations
-
Regulatory Approvals: Suppliers must secure approvals from agencies like the FDA, EMA, or respective national agencies to export bromocriptine mesylate.
-
Quality Standards: Top suppliers adhere to cGMP regulations, with certifications from WHO or other recognized authorities.
-
Manufacturing Capacity: Capacity varies significantly; large producers like Sun Pharma and Teva distribute globally, ensuring supply chain resilience amidst demand fluctuations.
Market Trends and Risks
-
Patent Expiry: Original patents lapsed in most regions around 2012–2014, opening markets to generics.
-
Pricing Pressure: Increased competition among generics has driven prices down, affecting supplier margins.
-
Supply Disruptions: Dependence on Indian and Israeli manufacturers poses risks from geopolitical tensions, regulatory delays, or pandemic-related disruptions.
-
Regulatory Environment: Stricter quality control and import/export regulations influence supplier operations and market access.
Summary
The primary suppliers of bromocriptine mesylate are generic manufacturers based mainly in India, Israel, and North America. The market has stabilized post-patent expiry, with large-scale producers sustaining global supply. Regulatory compliance and manufacturing capacity remain critical factors for market stability.
Key Takeaways
-
Bromocriptine mesylate is supplied mainly by generic pharmaceutical companies post-patent expiration.
-
Major producers include Sun Pharma, Cipla, Teva, and Mylan, with regional strengths depending on market access.
-
Supply chain security depends on manufacturing capacity, regulatory compliance, and geopolitical stability.
-
Price competition among generics has kept costs low but may affect production sustainability.
-
Global regulatory standards influence supplier qualification and export potential.
FAQs
1. Who are the leading manufacturers of bromocriptine mesylate globally?
Teva, Sun Pharma, Cipla, and Mylan are among the top producers, with manufacturing facilities in India, Israel, and North America.
2. What regions predominantly supply bromocriptine mesylate?
India supplies the largest volume due to its extensive generic manufacturing capacity, followed by Israel and North America.
3. Are there FDA-approved suppliers of bromocriptine mesylate?
Yes. Major international generic manufacturers comply with FDA standards, and several Indian companies hold approved manufacturing facilities.
4. Has the patent expiration impacted the supply chain?
Yes. It increased the number of generic suppliers, leading to price competition and wider distribution.
5. What risk factors might affect future bromocriptine mesylate supply?
Regulatory delays, geopolitical tensions, manufacturing disruptions, and quality compliance issues can impact ongoing supplies.
Sources
[1] U.S. Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
[2] European Medicines Agency. (2022). Marketing authorization for pharmaceuticals.
[3] IMS Health. (2020). Global Pharmaceutical Market Report.
